[{"address1": "101 Cambridgepark Drive", "city": "Cambridge", "state": "MA", "zip": "02140", "country": "United States", "phone": "617 945 9626", "website": "https://www.serestherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas J. DesRosier Esq., J.D.", "age": 69, "title": "Co-CEO, Co-President & Chief Legal Officer", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 707142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marella  Thorell CPA", "age": 57, "title": "Co-CEO, Co-President & CFO", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew R. Henn Ph.D.", "age": 49, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 643828, "exercisedValue": 0, "unexercisedValue": 474375}, {"maxAge": 1, "name": "Dr. Teresa L. Young Ph.D., R.Ph.", "age": 57, "title": "Executive VP and Chief Commercial & Strategy Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 606327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chris  McChalicher", "title": "Senior VP of Manufacturing, Quality, and Process Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dennis M. Walling M.D.", "title": "Senior VP of Clinical Development & Head of Clinical Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ann  Kurowski", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Brady", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Hensley", "title": "Assistant General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 13.86, "open": 13.93, "dayLow": 13.5091, "dayHigh": 14.27, "regularMarketPreviousClose": 13.86, "regularMarketOpen": 13.93, "regularMarketDayLow": 13.5091, "regularMarketDayHigh": 14.27, "payoutRatio": 0.0, "trailingPE": 15.931819, "forwardPE": -25.49091, "volume": 32628, "regularMarketVolume": 32628, "averageVolume": 159563, "averageVolume10days": 109930, "averageDailyVolume10Day": 109930, "bid": 10.11, "ask": 17.53, "bidSize": 2, "askSize": 2, "marketCap": 126832200, "fiftyTwoWeekLow": 6.53, "fiftyTwoWeekHigh": 24.665, "allTimeHigh": 1040.0, "allTimeLow": 6.53, "priceToSalesTrailing12Months": 361.3453, "fiftyDayAverage": 18.2006, "twoHundredDayAverage": 13.89795, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 160495584, "profitMargins": 15.367519, "floatShares": 6466920, "sharesOutstanding": 9046519, "sharesShort": 798666, "sharesShortPriorMonth": 936245, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0912, "heldPercentInsiders": 0.125, "heldPercentInstitutions": 0.25471002, "shortRatio": 6.09, "shortPercentOfFloat": 0.14829999, "impliedSharesOutstanding": 8754570, "bookValue": 4.986, "priceToBook": 2.8118732, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": -0.908, "netIncomeToCommon": 5394000, "trailingEps": 0.88, "forwardEps": -0.55, "lastSplitFactor": "1:20", "lastSplitDate": 1745280000, "enterpriseToRevenue": 457.252, "enterpriseToEbitda": -1.618, "52WeekChange": 0.001445055, "SandP52WeekChange": 0.1198014, "quoteType": "EQUITY", "currentPrice": 14.02, "targetHighPrice": 22.0, "targetLowPrice": 6.0, "targetMeanPrice": 16.0, "targetMedianPrice": 20.0, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 47638000, "totalCashPerShare": 5.435, "ebitda": -99167000, "totalDebt": 85253000, "quickRatio": 2.159, "currentRatio": 2.297, "totalRevenue": 351000, "debtToEquity": 195.1, "revenuePerShare": 0.04, "returnOnAssets": -0.40124, "returnOnEquity": 0.15955, "grossProfits": -5746000, "earningsGrowth": -0.919, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -64.03704, "financialCurrency": "USD", "symbol": "MCRB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "longName": "Seres Therapeutics, Inc.", "priceEpsCurrentYear": 10.462687, "fiftyDayAverageChange": -4.180599, "fiftyDayAverageChangePercent": -0.2296957, "twoHundredDayAverageChange": 0.122050285, "twoHundredDayAverageChangePercent": 0.008781891, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1762559109, "regularMarketTime": 1762549201, "exchange": "NMS", "messageBoardId": "finmb_222388947", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1435325400000, "postMarketChangePercent": 3.1383708, "postMarketPrice": 14.46, "postMarketChange": 0.43999958, "regularMarketChange": 0.160001, "regularMarketDayRange": "13.5091 - 14.27", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 159563, "fiftyTwoWeekLowChange": 7.4900002, "fiftyTwoWeekLowChangePercent": 1.1470138, "fiftyTwoWeekRange": "6.53 - 24.665", "fiftyTwoWeekHighChange": -10.645, "fiftyTwoWeekHighChangePercent": -0.43158323, "fiftyTwoWeekChangePercent": 0.1445055, "earningsTimestamp": 1762349400, "earningsTimestampStart": 1762349400, "earningsTimestampEnd": 1762349400, "earningsCallTimestampStart": 1762349400, "earningsCallTimestampEnd": 1762349400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.88, "epsForward": -0.55, "epsCurrentYear": 1.34, "regularMarketChangePercent": 1.15441, "regularMarketPrice": 14.02, "shortName": "Seres Therapeutics, Inc.", "displayName": "Seres Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]